在美国，对于无抑制剂的中重度血友病 A 患者，预防性依库珠单抗与预防性重组因子 VIII 的成本效益比较。
Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States.
机构信息
Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Yale College, New Haven, Connecticut, USA.
出版信息
Am J Hematol. 2023 Sep;98(9):E247-E250. doi: 10.1002/ajh.27014. Epub 2023 Jul 4.
PMID:37401660
Abstract
Prophylactic emicizumab is cost-ineffective in adults with moderate or mild hemophilia A without inhibitors at current pricing. The price of prophylactic emicizumab would need to decrease by >35% to become cost-effective in this patient population.
摘要
预防性依库珠单抗在目前定价下，对于无抑制剂的中重度或轻度血友病 A 成人患者不具有成本效益。预防性依库珠单抗的价格需要降低超过 35%，才能在该患者人群中具有成本效益。
Zotero 插件